Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.

ABSTRACT:

Introduction

Early multimodal treatment of severe sepsis, including the use of drotrecogin alfa (activated) (DrotAA) when indicated, is considered essential for optimum outcome. However, predicting which infected patients will progress to severe sepsis and the need for aggressive intervention continues to be problematic. We therefore wished to explore whether there were any potential early markers that might predict improved survival in response to early use of DrotAA in patients with severe sepsis. In particular, in the dynamic setting of severe sepsis, we postulated that changes in markers reflecting evolving rather than baseline clinical status might guide therapy.

Methods

Data on a cohort of 305 Canadian patients from the open label ENHANCE trial of DrotAA in severe seps

SUBMITTER: Hodder RV 

PROVIDER: S-EPMC2717441 | biostudies-literature | 2009

REPOSITORIES: biostudies-literature